ARX FY26 Preliminary Results
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The company reported total revenue significantly above its forecast, driven by robust sales in its Myriad portfolio, which saw substantial growth compared to the previous year. Aroa's CEO expressed satisfaction with the results and indicated that detailed audited results will be available at the end of May.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Aroa Biosurgery
- Symphony Randomised Control Trial Complete
- AROA Business Update Presentation
- AROA Business Update
- Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.
- Aroa Biosurgery H1 FY26 Results
Later from Aroa Biosurgery
- FY26 Appendix 4E and Full Year Results
- FY26 Full Year Results Presentation
- Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
- Symphony Significantly Improves DFU Healing
- Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers
Follow Aroa Biosurgery into a list and get an email when it puts out news.
Follow Aroa Biosurgery